Breaking Finance News

Clovis Oncology Inc (NASDAQ:CLVS) stock price target increased to $36.00, issued a report today by Janney Montgomery Scott

In a report announced on 09/21/2016 Janney Montgomery Scott bumped up the target of Clovis Oncology Inc (NASDAQ:CLVS) from $35.00 to $36.00 reporting a potential upside of 0.03%.

Previously on 8/24/2016, Mizuho Securities reported on Clovis Oncology Inc (NASDAQ:CLVS) increased the target price from $15.00 to $23.00. At the time, this indicated a possible downside of 0.00%.

Just yesterday Clovis Oncology Inc (NASDAQ:CLVS) traded 0.00% even at $34.83. Clovis Oncology Inc’s 50-day moving average is $22.24 and its 200-day moving average is $17.16. The last closing price is up 102.93% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 42,608 shares of CLVS traded hands, down from an average trading volume of 2,264,320

Recent Performance Chart

Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology Inc has 52 week low of $11.57 and a 52 week high of $109.18 and has a market capitalization of $0.

A total of 8 analysts have released a research note on Clovis Oncology Inc. Two analysts rating the company a strong buy, zero analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $17.50.

More About Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *